Ubs Group Ag Olema Pharmaceuticals, Inc. Put Options Transaction History
Ubs Group Ag
- $527 Billion
- Q4 2024
Put Options
0 transactions
| Quarter | Operation | Price Per put | puts change | puts Held | SEC Form |
|---|
Others Institutions Holding OLMA
# of Institutions
162Shares Held
71.9MCall Options Held
251KPut Options Held
6.7K-
Bain Capital Life Sciences Investors, LLC Boston, MA7.47MShares$37.1 Million11.76% of portfolio
-
Paradigm Biocapital Advisors LP New York, NY7.3MShares$36.3 Million1.62% of portfolio
-
Bvf Inc San Francisco, CA5.72MShares$28.4 Million1.25% of portfolio
-
Black Rock Inc. New York, NY4MShares$19.9 Million0.0% of portfolio
-
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct3.67MShares$18.2 Million0.05% of portfolio
About Olema Pharmaceuticals, Inc.
- Ticker OLMA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 40,419,600
- Market Cap $201M
- Description
- Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 1/2 clinical trial for the treatment of recurrent, local...